董事会议事规则 深圳市海普瑞药业集团股份有限公司 董事会议事规则 第一章 总则 第一条 为健全和规范深圳市海普瑞药业集团股份有限公司（以下简称"公 司"）董事会议事和决策程序，保证公司经营、管理工作的顺利进行，根据《中 华人民共和国公司法》（以下简称"公司法"）、《深圳证券交易所股票上市规则》、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》、 《香港联合交易所有限公司证券上市规则》（以下简称"《香港上市规则》"，"香 港联合交易所有限公司"以下简称"香港联交所"）及其他相关法律、法规规定和 《深圳市海普瑞药业集团股份有限公司章程》（以下简称"《公司章程》"），制定 本议事规则。 第二条 董事会是公司经营管理的决策机构，维护公司和全体股东的利益， 负责公司发展目标和重大经营活动的决策。 第三条 董事会下设董事会秘书办公室，处理董事会日常事务。董事会秘书 负责保管董事会资料。 第二章 董事会职权 第四条 公司董事会由 7 名董事组成，设董事长 1 人，董事会成员中包括 3 名独立董事。 第五条 董事会对股东大会负责，行使下列职权： （六）制订公司增加或者减少注册资本、发行债券或者其他证 ...

独立董事工作制度 深圳市海普瑞药业集团股份有限公司 独立董事工作制度 第一条 为进一步完善深圳市海普瑞药业集团股份有限公司（以下简称"公 司"）的法人治理结构及公司董事会结构，强化对内部董事及经理层的约束和激 励机制，保护中小股东及利益相关者的利益，促进公司的规范运作，根据《中华 人民共和国公司法》（以下简称"《公司法》"）、《上市公司独立董事管理办法》、 《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》、 《香港联合交易所有限公司证券上市规则》（以下简称"《香港上市规则》"，"香 港联合交易所有限公司"以下简称"香港联交所"）等公司股票上市地有关法律、 行政法规、部门规章和规范性文件以及《深圳市海普瑞药业集团股份有限公司章 程》（以下简称"《公司章程》"）的规定和要求，结合公司实际情况，制定本制 度。 公司董事会下设的薪酬与考核委员会、提名委员会、审计委员会，独立董事 应当过半数并担任召集人。审计委员会由独立董事中会计专业人士担任召集人。 第二条 公司独立董事是指不在公司担任除董事外的其他职务，并与其所受 聘公司及主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影 响其进行独 ...

Financial Performance - Total profit decreased by 78.46% to ¥181,174,862.02 compared to ¥841,095,361.37 in the previous year[6] - Net profit fell by 78.17% to ¥141,885,482.96 from ¥650,063,599.37 year-on-year[6] - Operating profit declined by 78.76% to ¥178,819,355.74, primarily due to reduced gross profit and increased investment losses[3] - Total operating revenue for the period was CNY 4,063,233,063.48, a decrease of 24.69% compared to the same period last year[25] - Net profit attributable to shareholders of the listed company was CNY 143,170,121.26, down 78.05% year-on-year[25] - Basic earnings per share decreased by 85.97% to CNY 0.0135[25] - The company reported a net profit of CNY 141,885,482.96 for the period, a decrease of 78.05% compared to the previous year[21] Cash Flow - Cash flow from operating activities improved by 67.47%, reaching -¥233,988,970.92, compared to -¥719,281,089.84 in the previous year[7] - The company's cash flow from operating activities showed a net outflow of CNY 233,988,970.92, an increase of 67.47% compared to the same period last year[25] - The net cash flow from operating activities for the current period was -233,988,970.92 CNY, compared to -719,281,089.84 CNY in the previous period[30] - The cash inflow from other operating activities was 47,790,265.82 CNY, down from 72,009,536.97 CNY in the previous period[30] - The company reported a decrease in cash outflow for purchasing goods and services, which was 3,633,091,884.41 CNY compared to 5,322,980,702.09 CNY in the previous period[32] Assets and Liabilities - The company’s total assets decreased by 63.85% in trading financial assets, dropping to ¥474,182,329.41 from ¥1,311,642,406.30[2] - As of September 30, 2023, the company's total assets amounted to approximately CNY 20.12 billion, a decrease from CNY 20.84 billion at the beginning of the year, reflecting a decline of about 3.47%[12] - The company's current assets totaled CNY 11.86 billion, down from CNY 12.39 billion, indicating a decrease of approximately 4.29%[15] - Total liabilities amounted to CNY 7,621,518,381.46, down from CNY 8,435,034,680.42[25] - Current liabilities totaled CNY 4,997,191,595.42, down from CNY 5,575,796,301.03 at the beginning of 2023, reflecting a reduction of approximately 10.4%[39] - The total liabilities decreased to CNY 7,621,518,381.46 from CNY 8,435,034,680.42, a reduction of approximately 9.6%[39] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 27,307[8] - The largest shareholder, Shenzhen Lerun Technology Co., Ltd., holds 32.31% of the shares, totaling 474,029,899 shares[8] - The company has a total of 10 major shareholders, with Shenzhen Lerun Technology Co., Ltd. holding 474,029,899 shares, representing approximately 4.09% of the total share capital[11] Investment and Development - The company reported a significant increase in long-term equity investments, which rose to CNY 666.69 million from CNY 989.39 million, indicating a decrease of about 32.61%[15] - The company is exploring new strategies for market expansion and product development, although specific details were not disclosed in the report[14] - The company is focusing on expanding its market presence and enhancing product development capabilities to drive future growth[41] Financial Accuracy and Reporting - The report for the third quarter has not been audited[43] - The board of directors guarantees the accuracy and completeness of the financial information disclosed in the quarterly report[46] - The company has confirmed that there are no false records or misleading statements in the quarterly report[47] - The financial information in the quarterly report is stated to be true, accurate, and complete by the responsible personnel[47]

Financial Performance - The company reported a significant increase in revenue, achieving a total of 70 million in the first half of 2023, reflecting a growth of 12% compared to the same period last year[2]. - The company reported a revenue of RMB 1.5 billion for the first half of 2023, representing a year-on-year increase of 15%[64]. - The net profit attributable to shareholders for the same period was RMB 300 million, up 20% compared to the previous year[64]. - The company's operating revenue for the reporting period was ¥2,712,899,392.07, a decrease of 27.82% compared to the same period last year[83]. - Net profit attributable to shareholders was ¥123,349,841.18, down 75.87% year-on-year[83]. - The net cash flow from operating activities was -¥542,751,701.14, representing a decline of 125.45% compared to the previous year[83]. - The company's heparin API business revenue was approximately RMB 698 million, a year-on-year decline of 56.63%[151]. - The company reported a total of CNY 357.09 million in new purchases of financial assets during the period[139]. - The company reported a net investment loss of ¥226,299,845.92, which accounted for -134.92% of total profit[162]. Strategic Focus and Growth - The company is focusing on expanding its global supply chain for raw materials to mitigate risks associated with price fluctuations and supply shortages, particularly for heparin raw materials[17]. - The company has established a pipeline of innovative drug candidates, with several in clinical stages, aiming for commercialization in the near future[19]. - The company is actively enhancing its CDMO services, benefiting from the growing demand in the biopharmaceutical market, which has seen an increase in client R&D budgets[18]. - The company is prioritizing the development of new technologies and products to strengthen its market position and drive future growth[19]. - The company plans to launch three new products in the next quarter, focusing on innovative drug formulations[64]. - The company is expanding its market presence in Southeast Asia, targeting a 30% market share by the end of 2024[64]. - A strategic acquisition of a local biotech firm is expected to enhance the company's R&D capabilities and product pipeline[64]. - The company is focusing on deepening partnerships with strategic allies to secure high-quality orders and enhance project reserves[18]. Risk Management - The company is implementing strategies to manage foreign exchange risks, as a significant portion of its revenue is derived from overseas markets, primarily in euros and US dollars[20]. - The company faces potential risks from changes in international laws, political environments, and trade sanctions affecting overseas operations[26]. - The company is enhancing quality control measures to mitigate product quality risks associated with complex production processes[31]. - The company is facing risks related to raw material supply constraints and the inability to timely pass on costs[36]. - The company has established a risk control mechanism for foreign exchange derivative trading to mitigate exchange rate fluctuations[39]. Investment and Financial Assets - The company has made strategic investments in several innovative drug development firms, which may impact its financial performance due to fluctuations in fair value[21]. - The company has not engaged in speculative derivative investments during the reporting period[41]. - The company’s financial derivative trading is based on self-owned funds and adheres to legal and prudent principles[39]. - The company reported a loss of 0.89 million CNY from the fair value change of RVX warrants during the reporting period[39]. - The company incurred a loss of 210.51 million CNY from foreign exchange derivative trading during the reporting period[39]. - The total financial assets at the end of the period amounted to approximately CNY 1.79 billion, reflecting a significant increase from the beginning of the period[139]. Market Position and Competition - The heparin raw material drug industry is highly competitive, with the company rapidly increasing market share in Europe through its proprietary enoxaparin sodium formulation[32]. - The company relies heavily on two main products: enoxaparin sodium formulation and heparin sodium raw materials, which poses a concentration risk[33]. - The company successfully won the first position in the eighth batch of national drug centralized procurement for its enoxaparin sodium formulation, which is expected to be a new growth point[101]. - The company is focusing on expanding its market share in China through active participation in drug procurement and leveraging its high-ranking bid advantages[101]. - The company is enhancing its sales network in the U.S. and establishing partnerships with various medical systems and distributors to drive business growth[151]. Research and Development - The company is engaged in both independent and collaborative R&D efforts to accelerate the launch of new drug varieties, including projects like H1710 and RVX-208[95]. - The company has developed approximately 200 different molecular structures in its CDMO business, supporting over 300 clinical trials[112]. - The company is currently developing a candidate drug in the oncology field that is in the preclinical stage, with 5 indications in global Phase III clinical trials[113]. - The company has established a long-term stable partnership with several well-known multinational pharmaceutical companies for heparin raw materials[111]. - The company has over 20 first-in-class drug candidates covering more than 30 indications through industrial and equity investments[113]. Corporate Governance - The company has undergone a board restructuring with several directors being elected or leaving due to term completion[24]. - The annual shareholders' meeting had an investor participation rate of 68.34%[29]. - The board has decided not to distribute cash dividends for this fiscal year, focusing on reinvestment for growth[64].

深圳市海普瑞药业集团股份有限公司 证券代码：002399 证券简称：海普瑞 公告编号：2023-037 公司于2023年8月21日召开第六届董事会第二次会议，审议通过了《关于聘 任陈娟女士为公司财务总监的议案》，同意聘任陈娟女士为公司财务总监（简历 附后），任期自本次董事会审议通过之日至公司第六届董事会任期届满之日止。 关于变更财务总监的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、财务总监辞职 深圳市海普瑞药业集团股份有限公司（以下简称"公司"）董事会于近日收 到公司财务总监向贤青先生的书面辞职报告。向贤青先生因个人工作安排申请辞 去公司财务总监职务。辞职后，向贤青先生不再担任公司任何职务。 根据《公司法》、《公司章程》等有关规定，向贤青先生的辞职报告自送达董 事会之日起生效。截至本公告披露日，向贤青先生未持有公司股份。 公司对向贤青先生任职期间为公司发展所做出的贡献表示衷心感谢。 二、聘任财务总监 公司独立董事就该事项发表了独立意见，同意聘任陈娟女士为公司财务总监。 《公司独立董事关于第六届董事会第二次会议相关事项的独立意见》刊登于信息 披露媒 ...

独立董事：吕川、黄鹏、易铭 二〇二三年八月二十二日 1 一、关于聘任陈娟女士为公司财务总监的议案 经审阅陈娟女士的履历材料，未发现有《公司法》第 146、147、148 条规定的 情况以及被中国证监会确定为市场禁入者，并且禁入尚未解除之现象，其任职资格 符合担任上市公司高级管理人员的条件，能够胜任所聘财务总监职务，公司提名、 聘任的程序符合《公司法》、《公司章程》的有关规定，合法有效。因此，我们同意 聘任陈娟女士为公司财务总监，任期自董事会审议通过之日至第六届董事会任期届 满之日止。 深圳市海普瑞药业集团股份有限公司独立董事 关于第六届董事会第二次会议相关事项的独立意见 根据《上市公司独立董事规则》、《深圳证券交易所上市公司自律监管指引第 1号——主板上市公司规范运作》及《公司章程》、公司《独立董事工作制度》的 有关规定，作为深圳市海普瑞药业集团股份有限公司（以下简称"公司"）的独立 董事，我们对第六届董事会第二次会议审议的相关议案进行审阅，现对相关事项发 表独立意见如下： ...

经与会董事认真审议并通过了以下议案： 证券代码：002399 证券简称：海普瑞 公告编号：2023-036 深圳市海普瑞药业集团股份有限公司 第六届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市海普瑞药业集团股份有限公司（以下简称"公司"）第六届董事会第 二次会议（以下简称"会议"）通知及议案于2023年8月16日以电子邮件的形式 发出，会议于2023年8月21日14:00以通讯方式召开。本次会议应参与表决董事7 人，实际以通讯方式参与表决董事7人。公司监事及高级管理人员列席会议，会 议由公司董事长李锂先生主持。本次会议的通知、召开以及参与表决董事人数均 符合相关法律法规及《公司章程》的有关规定。 附件：财务总监陈娟简历 陈娟女士，1975年生，中国国籍，无境外永久居留权，湖北大学经济学学士， 清华大学会计硕士，拥有CGMA全球特许管理会计师和FIPA澳大利亚资深公共 会计师资格证，具备超过20年大型跨国上市企业财务管理经验。2012年-2015年 先后任IBM系统集成（深圳）有限公司和联想系统集成（深圳）有限公司财务总 监； ...

深圳市海普瑞药业集团股份有限公司 2023 年第一季度报告 深圳市海普瑞药业集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 3.第一季度报告是否经审计 1 （一）主要会计数据和财务指标 | --- | --- | --- | --- | |-----------------------------------------------------|-------------------|-------------------|----------------------------------| | | 本报告期 | 上年同期 | 本报告期比上年同期 | | | | | 增减（ % ） | | 营业收入（元） | 1,301,021,684.04 | 1,910,323,745.74 | -31.90% | | 归属于上市公司股东的净利润（元） | 66,540,023.25 | 234,943,371 ...

证券代码：002399 证券简称：海普瑞 公告编号：2023-027 深圳市海普瑞药业集团股份有限公司 关于举行2022年度网上业绩说明会的公告 一、业绩说明会召开时间及投资者参与方式 时间：2023年4月14日（星期五）下午15:00-16:30 召开方式：网络 参与方式：投资者可通过"同花顺路演平台"（http://board.10jqka.com.cn/rs/） 或同花顺App端入口（同花顺App首页-搜索-路演平台）参与本次年度业绩说明 会 二、公司出席人员 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 公司董事长李锂先生、董事兼总经理单宇先生、独立董事吕川先生、董事会 秘书钱风奇先生及财务总监向贤青先生。 深圳市海普瑞药业集团股份有限公司（以下简称"公司"）将于2023年4月 14日（星期五）通过"同花顺路演平台"举行2022年度业绩网上说明会，具体如 下： 三、问题征集 （问题征集专题页面二维码） 欢迎广大投资者积极参与本次网上业绩说明会。 特此公告。 深圳市海普瑞药业集团股份有限公司 董事会 二〇二三年四月十二日 为充分尊重投资者、提升交流的针 ...

Dividend Distribution - The company plans to distribute a cash dividend of 1.00 yuan per 10 shares to all shareholders, based on a total of 1,467,296,204 shares[4]. - The company distributed a cash dividend of 0.35 yuan per 10 shares based on a total share capital of 1,467,296,204 shares, approved at the 2021 annual general meeting[92]. - The cash dividend policy complies with the company's articles of association and has been transparently executed[93]. Financial Performance - The company reported a revenue of RMB 1.5 billion for the fiscal year 2022, representing a year-over-year growth of 15%[39]. - The company's total revenue for 2022 was RMB 7,159,410,684.41, primarily from the production and sales of heparin raw materials and formulations, as well as contract development and manufacturing organization (CDMO) services[113]. - The net profit for the year reached CNY 714,687,211.31, a significant increase compared to CNY 233,383,425.18 from the previous year, representing a growth of about 206.5%[191]. - The company's operating profit improved to CNY 828,623,184.85, up from CNY 227,474,697.78, marking an increase of around 264.5%[191]. - The company reported a decrease in accounts payable from CNY 171,477,883.69 to CNY 99,991,386.43, a reduction of about 41.7%[187]. - The total liabilities reached CNY 8,406.56 million, compared to CNY 7,584.86 million in the previous period, marking an increase of approximately 10.8%[183]. Future Guidance and Growth - The company has set a revenue guidance for 2023 at RMB 1.8 billion, indicating a projected growth of 20%[39]. - User data showed an increase in active users by 20% to 2 million in the same period[39]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[46]. - New product development includes a breakthrough in monoclonal antibody technology, expected to launch in Q3 2023[46]. Compliance and Governance - The company has maintained its commitment to transparency, with all financial reports signed and stamped by responsible parties[24]. - The company retained Ernst & Young Hua Ming as the domestic auditor for the 2022 financial report, with total audit fees amounting to RMB 5.58 million and internal control audit fees of RMB 0.43 million[54]. - The audit committee reviewed and agreed on the annual financial reports and internal control evaluations for 2021[153]. - The company has established a series of plans to ensure timely and full repayment of its bonds, including dedicated departments and personnel, and strict execution of financial management plans[88]. Employee and Management Information - The total number of employees at the end of the reporting period was 2,366, with 936 in the parent company and 1,430 in major subsidiaries[158]. - The company has established a competitive salary system based on performance and capability, ensuring fair compensation across different positions[158]. - Total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 1,396.48 million[176]. Risk Management - The company has detailed its future risks and countermeasures in the annual report, highlighting the importance of investor awareness regarding investment risks[19]. - The company has not reported any changes in its main business operations since its listing[32]. - The company has not reported any major matters that require explanation during the reporting period[65]. Financial Health Indicators - The company's EBITDA to total debt ratio improved to 21.40%, an increase of 8.47% compared to the previous year[106]. - The current ratio decreased by 1.14% to 2.222, while the quick ratio dropped by 21.39% to 0.9946[106]. - The debt-to-asset ratio increased to 40.39%, up by 0.70% from the previous year[106]. - Interest coverage ratio improved significantly to 4.53, a 115.71% increase from 2.10 in the previous year[130]. Asset and Liability Management - The total assets increased to CNY 14,483,308,913.97 from CNY 14,324,415,709.31, reflecting a growth of approximately 1.11%[187]. - Non-current liabilities totaled CNY 2,830.77 million, slightly up from CNY 2,793.39 million, indicating a growth of about 1.3%[183]. - The company's capital reserve decreased to CNY 5,858.62 million from CNY 5,943.65 million, a decline of about 1.4%[183]. Strategic Investments - The company has invested RMB 200 million in sustainable practices, aiming for a 30% reduction in waste emissions by 2025[46]. - The company has established partnerships with leading technology firms to enhance its production processes and product offerings[46]. - The company has made strategic investments in new product development and technology, although specific figures are not provided in the content[194].